Authors
Latest:
Novel Detection Methods May End Chemotherapy for Patients With CRCA new genetic test that may allow patients with colorectal cancer to avoid chemotherapy after tumor resection is under investigation at AdventHealth Cancer Institute in Orlando, Florida.
Latest:
Evolving Treatment Landscape of MyelofibrosisClosing out their discussion on myelofibrosis management, experts from the John Theurer Cancer Center consider novel therapies under investigation and the future treatment paradigm.
Latest:
Dr. Ramaswamy on Capecitabine and Irinotecan Monotherapy in Gallbladder CancerAnant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.
Latest:
Dr Omene on the Importance of Access to Breast Cancer Screenings in Underserved PopulationsCoral O. Omene, MD, PhD, discusses the need to improve early access to breast cancer screenings for patients in underserved populations and recent updates to the National Comprehensive Cancer Network Guidelines on breast cancer screening.
Latest:
Ohio State Recruits Top Oncologist to Expand Cell Therapy Program, Lead Bone Marrow Transplant ServicesThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has recruited Marcos J. de Lima, MD, to lead its Blood and Marrow Transplant and Cellular Therapy programs, two key leadership positions within central Ohio’s only National Cancer Institute-designated comprehensive cancer center and largest freestanding hospital.
Latest:
Dr Lou on the Predictive and Prognostic Utility of Tumor Stroma Proportion in Ovarian CancerEmil Lou, MD, PhD, FACP, discusses the predictive and prognostic value of tumor stroma proportion for survival outcomes in ovarian cancer.
Latest:
UCSF Prostate Cancer Program Awarded SPORE Grant by National Cancer InstituteResearchers will investigate aggressive prostate cancer from a mechanistic, biomarker and therapeutic perspective.
Latest:
Earlier CAR T Use in Multiple Myeloma: Game Changer or Boutique Medicine?Krina K. Patel, MD, MSc, discusses her thoughts on moving CAR T-cell therapy up in the lines of treatment for patients with multiple myeloma.
Latest:
Dr Zarrabi on Questions Regarding the Use of Triplet Therapy in Prostate CancerKevin Kayvan Zarrabi, MD, MS, FACP, discusses remaining questions regarding treatment consisting of triplet therapy in patients with metastatic castration-sensitive prostate cancer.
Latest:
Dr. Dent on the Clinical Implications of the MONALEESA-2 Trial in HR+/HER2- Breast CancerSusan Faye Dent, MD, discusses the clinical implications of the phase 3 MONALEESA-2 trial in hormone receptor–positive, HER2-negative breast cancer.
Latest:
Overcoming Challenges With Molecular Testing in NSCLC, Other Solid TumorsMary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Latest:
Dr. Extermann on the Significance of Novel Treatment Options in HER2+ Breast CancerMartine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.
Latest:
The Evolving Treatment Landscape of Biliary Tract CancersClosing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.
Latest:
Dr Hays on Unmet Needs in CRCJohn L. Hays, MD, PhD, discusses unmet needs for patients with colorectal cancer and future directions for research in this disease.
Latest:
Clinical Scenario: Metastatic EBV-Positive NPCThe panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.
Latest:
Immunotherapy's Role in Improving Durability of Outcomes in Advanced Upper GI CancersSamuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.
Latest:
Dr Talcott on Treatment De-Escalation in Elderly Patients With Breast CancerWesley J. Talcott, MD, MBA, discusses the importance of de-escalating therapy in patients with breast cancer, highlighting use of personalized treatment approaches.
Latest:
Dr. Rajdev on Detecting HER2 Positivity in GI CancerLakshmi Rajdev, MD, MS, discusses detecting HER2 positivity in patients with gastrointestinal cancers.
Latest:
Closing Thoughts and Key Takeaways on Small Cell Lung CancerIn a forward-looking discussion, Ticiana Leal, MD; Anne Chiang, MD, PhD; Afshin Dowlati, MD; and Tarita O. Thomas, MD, PhD, offer their concluding insights on the evolving landscape of clinical trials and the future directions of small cell lung cancer (SCLC) treatment, highlighting promising areas of research and potential breakthroughs that may shape the management of this challenging disease in the years to come.
Latest:
Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCCViktor Grünwald, MD, PhD, on patterns of progression and subsequent therapy for patients with advanced RCC treated during the phase 3 CLEAR trial.
Latest:
Closing Thoughts on Evolving Antibody-Drug Conjugate LandscapeThe expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.
Latest:
Reviewing Best Practices in the Surgical Management of Breast Cancer: Post-Surgery Outcomes in Stage IV DiseaseIn this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.
Latest:
Direct Partnership With Patients May Accelerate Cancer Research and Precision OncologyDuring the past several decades, cancer research has produced revolutionary discoveries leading to dramatic results for many patients.
Latest:
Clinical Updates for the Management of Lung Cancer Brain MetastasesAs improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore.
Latest:
Dr Ducreux on the Potential Use of Liver Transplantation Plus Chemo for CRC Liver MetastasesMichel Ducreux, MD, PhD, discusses the rationale for the TRANSMET trial in patients with CRC liver metastases, highlighting the significance of data from the trial.
Latest:
Zhao on Existing Medical Conditions and Cancer Clinical Trial EnrollmentYayi Zhao, discusses how the prevalence of existing medical conditions and clinical factors may vary by race and effect eligibility for enrollment in clinical trials in patients with cancer.
Latest:
Dr Bertossi on the Role of Centralized Academic Reference Diagnostics and Biobanking in Clinical TrialsConsuelo Bertossi, MD, discusses centralized academic reference diagnostics and biobanking in prospective, multicenter clinical trials.
Latest:
Physicians Must Become Advocates to Play a Role in Community Oncology’s FutureAlthough some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.
Latest:
Dr Ramnaraign on Retrospective Data For irAEs in Older Patients With Kidney CancerBrian H. Ramnaraign, MD, discusses findings from a single-institution review of the incidence of immunotherapy-related toxicities in older patients with kidney cancer.
Latest:
Dr. Nichols on the Prognosis of Patients With VHL DiseaseKim E. Nichols, MD, discusses the prognosis of patients with von Hippel-Lindau disease.
.jpg?fit=crop&auto=format)
